Real-World-Feasible Immunohistochemistry of ATRX, DAXX, and Menin Identifies a Subgroup of Non-Functioning Pancreatic Neuroendocrine Tumors with low Recurrence Risk to Guide De-Escalating Surveillance.

Verschuur AVD, Hackeng WM, Jairam J, Eldem B, Westendorp JS, Vriens MR, Valk GD, Pea A, Salvia R, Lawlor RT, Scarpa A, Luchini C, Heaphy CM, Hong SM, Marinoni I, Perren A, Dreijerink KMA, van Dijkum EJMN, Sarasqueta AF, Singhi AD, Elias SG, Brosens LAA

Open source

DOI: 10.1007/s12022-026-09933-z
Published: 2026 Aug 29
Container: Endocrine pathology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12022-026-09933-z,
  title = {Real-World-Feasible Immunohistochemistry of ATRX, DAXX, and Menin Identifies a Subgroup of Non-Functioning Pancreatic Neuroendocrine Tumors with low Recurrence Risk to Guide De-Escalating Surveillance.},
  author = {Verschuur AVD and Hackeng WM and Jairam J and Eldem B and Westendorp JS and Vriens MR and Valk GD and Pea A and Salvia R and Lawlor RT and Scarpa A and Luchini C and Heaphy CM and Hong SM and Marinoni I and Perren A and Dreijerink KMA and van Dijkum EJMN and Sarasqueta AF and Singhi AD and Elias SG and Brosens LAA},
  year = {2026},
  journal = {Endocrine pathology},
  doi = {10.1007/s12022-026-09933-z},
  url = {https://doi.org/10.1007/s12022-026-09933-z}
}

RIS

TY  - JOUR
TI  - Real-World-Feasible Immunohistochemistry of ATRX, DAXX, and Menin Identifies a Subgroup of Non-Functioning Pancreatic Neuroendocrine Tumors with low Recurrence Risk to Guide De-Escalating Surveillance.
AU  - Verschuur AVD
AU  - Hackeng WM
AU  - Jairam J
AU  - Eldem B
AU  - Westendorp JS
AU  - Vriens MR
AU  - Valk GD
AU  - Pea A
AU  - Salvia R
AU  - Lawlor RT
AU  - Scarpa A
AU  - Luchini C
AU  - Heaphy CM
AU  - Hong SM
AU  - Marinoni I
AU  - Perren A
AU  - Dreijerink KMA
AU  - van Dijkum EJMN
AU  - Sarasqueta AF
AU  - Singhi AD
AU  - Elias SG
AU  - Brosens LAA
PY  - 2026
JO  - Endocrine pathology
DO  - 10.1007/s12022-026-09933-z
UR  - https://doi.org/10.1007/s12022-026-09933-z
ER  -

APA

AVD, V., WM, H., J, J., B, E., JS, W., MR, V., GD, V., A, P., R, S., RT, L., A, S., C, L., CM, H., SM, H., I, M., A, P., KMA, D., EJMN, V. D., AF, S., AD, S., SG, E., & LAA, B. (2026). Real-World-Feasible Immunohistochemistry of ATRX, DAXX, and Menin Identifies a Subgroup of Non-Functioning Pancreatic Neuroendocrine Tumors with low Recurrence Risk to Guide De-Escalating Surveillance.. Endocrine pathology. https://doi.org/10.1007/s12022-026-09933-z

Source records

pubmed · retrieved 2026-09-26T03:54:24.672Z